---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-011748"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:42:15.143970+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cytek sees Q4 rev $62M (+8% YoY); FY2025 rev ~$201M

## Summary
- Preliminary Q4 2025 revenue of ~$62M, up 8% YoY and 19% QoQ.
- Full-year 2025 revenue estimated at ~$201M.
- CEO cites strong Services, Reagents and APAC instrument growth; EMEA returns to positive instrument sales.
- Company to present at JP Morgan Healthcare Conference on Jan 14, 2026.
- Full Q4 and FY results with 2026 guidance expected late February 2026.

## SEC filing metadata
- accession: 0001193125-26-011748
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312526011748/0001193125-26-011748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312526011748/d41645d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-011748
- JSON: https://secwatch.observer/filing/0001193125-26-011748.json
- Plain text: https://secwatch.observer/filing/0001193125-26-011748.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.